Federation Des Caisses Desjardins Du Quebec Intellia Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.9 Billion
- Q3 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 181 shares of NTLA stock, worth $2,181. This represents 0.0% of its overall portfolio holdings.
Number of Shares
181
Previous 181
-0.0%
Holding current value
$2,181
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding NTLA
# of Institutions
314Shares Held
91.5MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$148 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$116 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$116 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$62 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$59.6 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $916M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...